研究者業績

Takuo Katsumoto

  (勝本 拓夫)

Profile Information

Affiliation
Fujita Health University
Degree
医学博士(Mar, 2004, 千葉大学)

Researcher number
50469970
J-GLOBAL ID
200901066555884752
researchmap Member ID
5000092299

Research Interests

 3

Education

 3

Major Papers

 26
  • Takuo Katsumoto, Yoko Ogawara, Kazutsune Yamagata, Yukiko Aikawa, Ryo Goitsuka, Takuro Nakamura, Issay Kitabayashi
    Blood Advances, 6(19) 5527-5537, Aug 10, 2022  Peer-reviewedLead author
    MOnocytic leukemia Zinc finger protein (MOZ, MYST3, or KAT6A) is a MYST-type acetyltransferase involved in chromosomal translocation in acute myelogenous leukemia (AML) and myelodysplastic syndrome. MOZ is established as essential for hematopoiesis; however, the role of MOZ in AML has not been addressed. We propose that MOZ is critical for AML development induced by MLL-AF9, MLL-AF10, or MOZ-TIF2 fusions. Moz-deficient hematopoietic stem/progenitor cells (HSPCs) transduced with an MLL-AF10 fusion gene neither formed colonies in methylcellulose nor induced AML in mice, and Moz-deficient HSPCs bearing MLL-AF9 also generated significantly reduced colony and cell numbers. Moz-deficient HSPCs expressing MOZ-TIF2 could form colonies in vitro but could not induce AML in mice. By contrast, Moz was dispensable for colony formation by HOXA9-transduced cells and AML development caused by HOXA9 and MEIS1, suggesting a specific requirement for MOZ in AML induced by MOZ/MLL-fusions. Expression of the Hoxa9 and Meis1 genes was decreased in Moz-deficient MLL-fusion expressing cells, while expression of Meis1, but not Hoxa9, was reduced in Moz-deficient MOZ-TIF2 AML cells. AML development induced by MOZ-TIF2 was rescued by introducing Meis1 into Moz-deficient cells carrying MOZ-TIF2. Meis1 deletion impaired MOZ-TIF2¬-mediated AML development. MOZ-TIF2 and endogenous Moz binding and active histone modifications were also severely reduced at the Meis1 locus in Moz-deficient MOZ-TIF2 and MLL-AF9 AML cells. These results suggest that endogenous MOZ is critical for MOZ/MLL-fusion-induced AML development and maintains fusion binding and active chromatin signatures at target gene loci.
  • Takuo Katsumoto, Naomi Yoshida, Issay Kitabayashi
    CANCER SCIENCE, 99(8) 1523-1527, Aug, 2008  Peer-reviewedLead author
  • T Katsumoto, Y Aikawa, A Iwama, S Ueda, H Ichikawa, T Ochiya, Kitabayashi, I
    GENES & DEVELOPMENT, 20(10) 1321-1330, May, 2006  Peer-reviewedLead author
  • T Katsumoto, M Kimura, M Yamashita, H Hosokawa, K Hashimoto, A Hasegawa, M Omori, T Miyamoto, M Taniguchi, T Nakayama
    JOURNAL OF IMMUNOLOGY, 173(8) 4967-4975, Oct, 2004  Peer-reviewedLead author

Misc.

 19

Professional Memberships

 1

Research Projects

 8